{
    "2020-01-03": [
        [
            {
                "time": "",
                "original_text": "万泰生物获得IPO“通行证”，销售费用高企陷商业贿赂“疑云”",
                "features": {
                    "keywords": [
                        "万泰生物",
                        "IPO",
                        "通行证",
                        "销售费用",
                        "高企",
                        "商业贿赂",
                        "疑云"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}